Personalizing health care: feasibility and future implications (Q34938911)

5 August 2017

4 references

25 June 2019

12 September 2020

14 November 2020

26 June 2021

Personalizing health care: feasibility and future implications (English)

1 reference

5 August 2017

1 reference

12 September 2020

1 reference

14 November 2020

1 reference

26 June 2021

Laura McCullagh

30

0 references

Stephen Campbell

Stephen Campbell

13

0 references

Lars L. Gustafsson

Lars L Gustafsson

45

0 references

Rickard E Malmström

7

Rickard E Malmström

1 reference

5 August 2017

1

Brian Godman

1 reference

5 August 2017

10

Marion Bennie

1 reference

5 August 2017

12

Anna Bucsics

1 reference

5 August 2017

15

Alessandra Ferrario

1 reference

5 August 2017

16

Jurij Fürst

1 reference

5 August 2017

20

Alan Haycox

1 reference

5 August 2017

22

Krystyna Hviding

1 reference

5 August 2017

21

Harald Herholz

1 reference

5 August 2017

23

Saira Jan

1 reference

5 August 2017

24

Marija Kalaba

1 reference

5 August 2017

25

Christina Kvalheim

1 reference

5 August 2017

26

Ott Laius

1 reference

5 August 2017

28

Kamila Malinowska

1 reference

5 August 2017

32

Ken Paterson

1 reference

5 August 2017

34

Gisbert Selke

1 reference

5 August 2017

35

Catherine Sermet

1 reference

5 August 2017

36

Steven Simoens

1 reference

5 August 2017

37

Dominik Tomek

1 reference

5 August 2017

Vera Vlahovic-Palcevski

38

Vera Vlahovic-Palcevski

1 reference

5 August 2017

40

Magdalena Wladysiuk

1 reference

5 August 2017

41

Menno van Woerkom

1 reference

5 August 2017

43

Corrine Zara

1 reference

5 August 2017

14

Eduardo Diogene

1 reference

5 August 2017

9

Christoph Baumgärtel

1 reference

5 August 2017

17

Kristina Garuoliene

1 reference

5 August 2017

Alexander E Finlayson

2

Alexander E Finlayson

1 reference

5 August 2017

Parneet K Cheema

3

1 reference

5 August 2017

Eva Zebedin-Brandl

4

1 reference

5 August 2017

Inaki Gutiérrez-Ibarluzea

5

1 reference

5 August 2017

Jan Jones

6

1 reference

5 August 2017

Elina Asola

8

1 reference

5 August 2017

Iain Bishop

11

1 reference

5 August 2017

Miguel Gomes

18

1 reference

5 August 2017

Katharine Harris

19

1 reference

5 August 2017

Sven-Ake Lööv

27

1 reference

5 August 2017

Andrew Martin

29

1 reference

5 August 2017

Fredrik Nilsson

31

1 reference

5 August 2017

Ulrich Schwabe

33

1 reference

5 August 2017

Luka Voncina

39

1 reference

5 August 2017

Durhane Wong-Rieger

42

1 reference

5 August 2017

Raghib Ali

44

1 reference

5 August 2017

language of work or name

English

0 references

publication date

13 August 2013

5 references

5 August 2017

25 June 2019

12 September 2020

14 November 2020

26 June 2021

5 references

5 August 2017

25 June 2019

12 September 2020

14 November 2020

26 June 2021

11

1 reference

5 August 2017

179

1 reference

Creative Commons Attribution

5 August 2017

4 references

25 June 2019

12 September 2020

14 November 2020

26 June 2021

0 references

https://scigraph.springernature.com/pub.10.1186/1741-7015-11-179

0 references

cites work

Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Epigenetic mechanisms and therapeutic perspectives for neurodevelopmental disorders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Generic medicines: solutions for a sustainable drug market?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Personalized medicine in psychiatry: problems and promises

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Functionalizing genomic data for personalization of medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Emerging strategies for the dual inhibition of HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

An integrated map of genetic variation from 1,092 human genomes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Stratified medicine and reimbursement issues

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Insights from genome-wide association studies of drug response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pertuzumab in HER2-positive breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenomics and individualized medicine: translating science into practice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Recent advances in novel targeted therapies for HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Personalized medicine policy challenges: measuring clinical utility at point of care

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

A genetic inference on cancer immune responsiveness

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

International variability in the reimbursement of cancer drugs by publically funded drug programs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Personalized medicine: is it a pharmacogenetic mirage?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Personalized cancer medicine - a strategy to counteract an increasing cancer challenge

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Paying for personalized care: cancer biomarkers and comparative effectiveness

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Systems pharmacology of complex diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Hormonal therapy in breast cancer: a model disease for the personalization of cancer care

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The prevalence and cost of unapproved uses of top-selling orphan drugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Structural and genic characterization of stable genomic regions in breast cancer: relevance to chemotherapy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Access to orphan drugs in Europe: current and future issues

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Crizotinib: in locally advanced or metastatic non-small cell lung cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Role of genotyping in non-small cell lung cancer treatment: current status

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Health technology assessment and private payers' coverage of personalized medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenetics: past, present and future

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Using genome-wide association studies to identify genes important in serious adverse drug reactions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Adverse drug reactions in patients admitted on internal medicine wards in a district and regional hospital in Uganda

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Perspectives on epigenetics and its relevance to adverse drug reactions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenomics: the genetics of variable drug responses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of Knowledge by Science and Society Partnership for Global Personalized Medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Genomics and drug response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

What principles should govern the use of managed entry agreements?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Effect of direct-to-consumer genomewide profiling to assess disease risk

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Evidence-based medicine in the era of biomarkers: teaching a new dog old tricks?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Forecasting drug utilization and expenditure in a metropolitan health region

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Clinical assessment incorporating a personal genome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Review of the clinical studies using the 21-gene assay.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Personalized medicine in psychiatry: ethical challenges and opportunities.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Economic opportunities and challenges for pharmacogenomics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Balancing innovation, access, and profits--market exclusivity for biologics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Surrogate outcomes in health technology assessment: an international comparison

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacoepigenetics: its role in interindividual differences in drug response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Estimation of the warfarin dose with clinical and pharmacogenetic data

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Cytochrome p-450 polymorphisms and response to clopidogrel

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Genetic determinants of response to clopidogrel and cardiovascular events

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenetics in drug discovery and development: a translational perspective

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Balancing Big Pharma's books

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

HLA-B*5701 screening for hypersensitivity to abacavir

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Cost of cancer care: issues and implications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Hospitalisations and emergency department visits due to drug-drug interactions: a literature review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

How much will Herceptin really cost?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Ethical and clinical practice considerations for genetic counselors related to direct-to-consumer marketing of genetic tests

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Clinical genomics data standards for pharmacogenetics and pharmacogenomics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Drug withdrawals and the lessons within.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Cancer: a Systems Biology disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Ethical, legal, and social implications of genomic medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Research methods used in developing and applying quality indicators in primary care.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenomics: the promise of personalized medicine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Molecular portraits of human breast tumours

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The safety of newly approved medicines: do recent market removals mean there is a problem?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenomics steps toward personalized medicine

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Health technology assessment in the era of personalized health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Phase III and submission failures: 2007–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Personalized medicine. New cystic fibrosis drug offers hope, at a price.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Delivering affordable cancer care in high-income countries

21 January 2018

2 references

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

What evidence is there for the reimbursement of personalised medicine?

26 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Direct-to-consumer genetic testing: regulating offer or use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Personalizing healthcare: from genetics through payment to improving care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

The microeconomics of personalized medicine: today's challenge and tomorrow's promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Circulating tumour cells in non-metastatic breast cancer: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Integrating molecular diagnostics into anticancer drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Early accelerated approval for highly targeted cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Clopidogrel, genetics, and drug responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Pharmacogenomics: "noninferiority" is sufficient for initial implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

The Italian Horizon Scanning Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

What is the clinical utility of genetic testing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Early awareness and alert systems: an overview of EuroScan methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Evaluating the utility of personal genomic information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

The ongoing regulation of generic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

21 January 2018

2011 FDA drug approvals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Hepatitis B virus (HBV) genotypes in a group of Sri Lankan patients with chronic infection.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenomics, ethics, and public policy.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

Pharmacogenetic tests: the need for a level playing field

26 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

21 January 2018

Defining quality of care

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Evaluation of risk prediction updates from commercial genome-wide scans

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Personalized medicine: how much can we afford? A bioethics perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Pharmacogenomic Testing: Knowing More, Doing Better

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-11-179

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3750765

The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants

9 December 2018

1 reference

12 December 2020

Polygenes, risk prediction, and targeted prevention of breast cancer

1 reference

12 December 2020

Challenges and opportunities for evidence-based genetics practice

1 reference

12 December 2020

Targeted cancer therapies

1 reference

12 December 2020

What is clinical utility and why should we care?

1 reference

12 December 2020

Pharmacogenomics at the tipping point: challenges and opportunities

1 reference

12 December 2020

Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts

1 reference

12 December 2020

Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia

1 reference

12 December 2020

European countries with small populations can obtain low prices for drugs: Lithuania as a case history

1 reference

12 December 2020

Natalizumab for multiple sclerosis: a complicated treatment

1 reference

12 December 2020

Time to revisit the orphan drug law

1 reference

12 December 2020

The danger of imperfect regulation: OxyContin use in the United States and Canada

1 reference

12 December 2020

Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

1 reference

12 December 2020

Impact of genomics on personalized cancer medicine

1 reference

12 December 2020

Personalized medicine: a personal view

1 reference

12 December 2020

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned

1 reference

12 December 2020

Improving the managed entry of new medicines: sharing experiences across Europe

1 reference

12 December 2020

Discovery of new treatments in the context of delivering personalized medicine

1 reference

12 December 2020

Public health perspective: from personalized medicine to personal health

1 reference

12 December 2020

Toward the integration of personalized and systems medicine: challenges, opportunities and approaches

1 reference

12 December 2020

Differences in US healthcare coverage policies in BRCA testing and potential implications

1 reference

12 December 2020

Towards a unified concept of individualized medicine

1 reference

12 December 2020

Market access challenges in the EU for high medical value diagnostic tests

1 reference

12 December 2020

Legal pressures and incentives for personalized medicine

1 reference

12 December 2020

1 reference

12 December 2020

Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research

1 reference

12 December 2020

Identifiers

DOI

10.1186/1741-7015-11-179

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference